Therapeutic drug monitoring and neutralizing anti-drug antibody detection to optimize TNF-alpha inhibitor treatment for uveitis
BackgroundAdalimumab taken every other week is an effective treatment in patients with chronic refractory uveitis. Patients who have a suboptimal response to this treatment may suffer from recurrent inflammation and vision loss. Here, we investigated the use of therapeutic drug monitoring and neutra...
Saved in:
Main Authors: | Howard C. Chen, Jenny Shunyakova, Amit K. Reddy, Srujay Pandiri, Lynn Hassman |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-01-01
|
Series: | Frontiers in Ophthalmology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fopht.2025.1432935/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy of adalimumab in pediatric non-infectious uveitis with and without anterior segment inflammation
by: Chunbo Zhang, et al.
Published: (2025-01-01) -
Involvement of HLADQA1*05 in Patients with Inflammatory Bowel Disease Treated with Anti-TNF Drugs
by: Anna Pau, et al.
Published: (2025-01-01) -
The Efficacy of Adalimumab Treatment in Pediatric Non-Infectious Uveitis: A Retrospective Cohort Study
by: Kübra Özdemir Yalçınsoy, et al.
Published: (2024-12-01) -
Efficiency and safety of one-year anti-TNF-α treatment in Crohn’s disease: a Polish single-centre experience
by: Marcin Sochal, et al.
Published: (2019-12-01) -
Biosimilars in Focus: Evaluating Their Role Compared to Adalimumab in Clinical Practice
by: Dorota Waz, et al.
Published: (2025-01-01)